Novavax earns $125M Sanofi milestone, raises 2026 revenue outlook
Novavax said Sanofi's Phase 3 flu-COVID combination vaccine trial start in Europe triggered a $125 million payment, as the company lifted its full-year revenue framework.
SEC filing
2 stories
Novavax said Sanofi's Phase 3 flu-COVID combination vaccine trial start in Europe triggered a $125 million payment, as the company lifted its full-year revenue framework.
SEC filing
Sanofi's Phase 3 trial combining its high-dose flu shot with Novavax's Nuvaxovid reached its fifth dosed patient, activating the payment.
SEC filing